Clinical Scorecard: HPV Genotype Distribution Among Unvaccinated Males Aged 16 to 20 in Quebec, Canada
At a Glance
Category
Detail
Condition
Human papillomavirus (HPV) infection
Key Mechanisms
Transmission through sexual contact; vaccine-targeted genotypes reduced by herd immunity
Target Population
Unvaccinated sexually active males aged 16 to 20 years in Quebec
Care Setting
Community and school-based settings in Quebec, Canada
Key Highlights
HPV prevalence among unvaccinated males aged 16–20 was 18.4%, with <1% harboring quadrivalent HPV vaccine-targeted genotypes.
Strong herd immunity observed in young adult males due to high (>90%) HPV vaccination coverage in females.
Age, number of lifetime sexual partners, and history of other sexually transmitted infections independently associated with HPV positivity.
Guideline-Based Recommendations
Diagnosis
Use self-collected penile swabs for HPV detection and genotyping (e.g., Anyplex II-HPV28 assay).
Verify vaccination status through official vaccination registries.
Management
Implement school-based HPV vaccination programs targeting both girls and boys to achieve high coverage.
Consider mixed vaccine schedules (nonavalent + bivalent) for immunization to optimize protection.
Monitoring & Follow-up
Conduct prevalence studies among unvaccinated populations to assess herd immunity effects.
Monitor HPV genotype distribution to evaluate vaccine schedule effectiveness.
Risks
Sexual activity with multiple partners and history of other STIs increase risk of HPV infection.
Men who have sex with men may have higher prevalence of vaccine-targeted HPV genotypes.
Patient & Prescribing Data
Unvaccinated sexually active males aged 16 to 20 years in Quebec, Canada
Low prevalence of vaccine-targeted HPV genotypes suggests indirect protection from female vaccination programs; mixed vaccine schedules are safe and immunogenic.
Clinical Best Practices
Verify vaccination status before HPV prevalence or vaccine efficacy studies to account for herd immunity.
Target vaccination programs to both sexes early (grade 4) to maximize herd immunity and reduce HPV circulation.
Use mixed vaccine schedules combining nonavalent and bivalent HPV vaccines to balance immunogenicity and cost.
